Compare · AVAH vs WGS
AVAH vs WGS
Side-by-side comparison of Aveanna Healthcare Holdings Inc. (AVAH) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVAH and WGS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- AVAH is the larger of the two at $2.89B, about 1.6x WGS ($1.86B).
- WGS has been more active in the news (5 items in the past 4 weeks vs 1 for AVAH).
- AVAH has more recent analyst coverage (22 ratings vs 8 for WGS).
- Company
- Aveanna Healthcare Holdings Inc.
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $2.89B
- $1.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 1
- 5
- Recent ratings
- 22
- 8
Aveanna Healthcare Holdings Inc.
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children; nursing services in school settings in which our caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; unskilled nursing services; and employer of record support services, as well as in-clinic and home-based pediatric therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers a line of durable medical equipment and enteral nutrition supplies to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Latest AVAH
- Aveanna Announces Third Quarter 2026 Earnings Release Date and Conference Call
- SEC Form 4 filed by Aveanna Healthcare Holdings Inc.
- Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Leadership Update
- Aveanna to Participate in the Deutsche Bank 2026 Healthcare Summit
- Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference
- Large owner J.H. Whitney Equity Partners Vii, Llc sold $169,579,886 worth of shares (14,746,077 units at $11.50) (SEC Form 4)
- Large owner Williams Robert M Jr sold $192,625,023 worth of shares (16,750,002 units at $11.50) (SEC Form 4)
- Large owner Vigano Paul R sold $192,625,023 worth of shares (16,750,002 units at $11.50) (SEC Form 4)
- Chief Administrative Officer Reisz Edwin C. sold $575,000 worth of shares (50,000 units at $11.50), decreasing direct ownership by 3% to 1,397,897 units (SEC Form 4)
- Chief Executive Officer Shaner Jeff sold $1,035,000 worth of shares (90,000 units at $11.50), decreasing direct ownership by 3% to 2,561,972 units (SEC Form 4)
Latest WGS
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)